AR129296A1 - Composiciones farmacéuticas de glp1 - Google Patents
Composiciones farmacéuticas de glp1Info
- Publication number
- AR129296A1 AR129296A1 ARP230101165A ARP230101165A AR129296A1 AR 129296 A1 AR129296 A1 AR 129296A1 AR P230101165 A ARP230101165 A AR P230101165A AR P230101165 A ARP230101165 A AR P230101165A AR 129296 A1 AR129296 A1 AR 129296A1
- Authority
- AR
- Argentina
- Prior art keywords
- glp1
- pharmaceutical compositions
- fluoro
- oxomidazol
- dimethyloxan
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Obesity (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263340591P | 2022-05-11 | 2022-05-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR129296A1 true AR129296A1 (es) | 2024-08-07 |
Family
ID=86732348
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP230101165A AR129296A1 (es) | 2022-05-11 | 2023-05-11 | Composiciones farmacéuticas de glp1 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20250302809A1 (enExample) |
| EP (1) | EP4522129A1 (enExample) |
| JP (1) | JP7767651B2 (enExample) |
| KR (1) | KR20250002778A (enExample) |
| CN (1) | CN119173255A (enExample) |
| AR (1) | AR129296A1 (enExample) |
| AU (1) | AU2023269995A1 (enExample) |
| CA (1) | CA3253043A1 (enExample) |
| CL (1) | CL2024003392A1 (enExample) |
| CO (1) | CO2024015285A2 (enExample) |
| DO (1) | DOP2024000232A (enExample) |
| IL (1) | IL316629A (enExample) |
| MX (1) | MX2024013839A (enExample) |
| PE (1) | PE20251285A1 (enExample) |
| TW (2) | TWI867526B (enExample) |
| WO (1) | WO2023220109A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12234236B1 (en) | 2023-09-14 | 2025-02-25 | Ascletis Pharma (China) Co., Limited | GLP-1R agonist and therapeutic method thereof |
| WO2025108361A1 (zh) * | 2023-11-21 | 2025-05-30 | 江苏恒瑞医药股份有限公司 | 杂环类化合物、其制备方法及其在医药上的应用 |
| TW202521534A (zh) | 2023-11-24 | 2025-06-01 | 香港商歌禮製藥(中國)有限公司 | Glp-1r 激動劑及其治療方法 |
| WO2025189141A1 (en) | 2024-03-08 | 2025-09-12 | Annapurna Bio, Inc. | Methods for treating obesity and increasing weight loss |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004520398A (ja) * | 2001-01-18 | 2004-07-08 | ファルマシア・アンド・アップジョン・カンパニー | 経口生物学的利用能が改善されたパクリタキセルの化学療法マイクロエマルジョン組成物 |
| US7115565B2 (en) * | 2001-01-18 | 2006-10-03 | Pharmacia & Upjohn Company | Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability |
| CA2662748A1 (en) * | 2006-09-08 | 2008-03-13 | Merck & Co., Inc. | Liquid pharmaceutical formulations for oral administration of a cgrp antagonist |
| JOP20190060A1 (ar) * | 2016-09-26 | 2019-03-26 | Chugai Pharmaceutical Co Ltd | مشتق بيرازولو بيريدين له تأثير مساعد لمستقبل glp-1 |
| JP7461104B2 (ja) * | 2017-11-29 | 2024-04-03 | 中外製薬株式会社 | Ｇｌｐ－１受容体アゴニスト作用を持つピラゾロピリジン誘導体を含有する医薬組成物 |
| TW202446384A (zh) | 2018-12-07 | 2024-12-01 | 美商紐羅克里生物科學有限公司 | 用於治療先天性腎上腺增生之crf1受體拮抗劑、醫藥配方及其固體形式 |
| US11884672B2 (en) | 2019-05-14 | 2024-01-30 | Vertex Pharmaceuticals Incorporated | Modulators of alpha-1 antitrypsin |
| ES3040117T3 (en) | 2020-09-09 | 2025-10-28 | Crinetics Pharmaceuticals Inc | Formulations of a somatostatin modulator |
| IL316478A (en) | 2022-05-11 | 2024-12-01 | Lilly Co Eli | GLP1 tablet preparations |
-
2023
- 2023-05-10 KR KR1020247040462A patent/KR20250002778A/ko active Pending
- 2023-05-10 WO PCT/US2023/021637 patent/WO2023220109A1/en not_active Ceased
- 2023-05-10 AU AU2023269995A patent/AU2023269995A1/en active Pending
- 2023-05-10 EP EP23729579.5A patent/EP4522129A1/en active Pending
- 2023-05-10 PE PE2024002463A patent/PE20251285A1/es unknown
- 2023-05-10 CA CA3253043A patent/CA3253043A1/en active Pending
- 2023-05-10 CN CN202380039380.7A patent/CN119173255A/zh active Pending
- 2023-05-10 JP JP2024566219A patent/JP7767651B2/ja active Active
- 2023-05-10 US US18/864,210 patent/US20250302809A1/en active Pending
- 2023-05-10 IL IL316629A patent/IL316629A/en unknown
- 2023-05-11 TW TW112117510A patent/TWI867526B/zh active
- 2023-05-11 TW TW113144409A patent/TW202508581A/zh unknown
- 2023-05-11 AR ARP230101165A patent/AR129296A1/es unknown
-
2024
- 2024-11-06 CL CL2024003392A patent/CL2024003392A1/es unknown
- 2024-11-08 CO CONC2024/0015285A patent/CO2024015285A2/es unknown
- 2024-11-08 MX MX2024013839A patent/MX2024013839A/es unknown
- 2024-11-11 DO DO2024000232A patent/DOP2024000232A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CL2024003392A1 (es) | 2025-03-14 |
| PE20251285A1 (es) | 2025-05-14 |
| US20250302809A1 (en) | 2025-10-02 |
| KR20250002778A (ko) | 2025-01-07 |
| DOP2024000232A (es) | 2024-12-30 |
| EP4522129A1 (en) | 2025-03-19 |
| JP7767651B2 (ja) | 2025-11-11 |
| CN119173255A (zh) | 2024-12-20 |
| TW202508581A (zh) | 2025-03-01 |
| WO2023220109A1 (en) | 2023-11-16 |
| TW202410894A (zh) | 2024-03-16 |
| CA3253043A1 (en) | 2023-11-16 |
| CO2024015285A2 (es) | 2024-11-28 |
| TWI867526B (zh) | 2024-12-21 |
| IL316629A (en) | 2024-12-01 |
| JP2025515706A (ja) | 2025-05-20 |
| MX2024013839A (es) | 2024-12-06 |
| AU2023269995A1 (en) | 2024-11-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR129296A1 (es) | Composiciones farmacéuticas de glp1 | |
| Ellepola et al. | Oral candidal infections and antimycotics | |
| DOP2024000235A (es) | Composiciones de comprimidos de glp1 | |
| PE20081266A1 (es) | Anticuerpos e inmunoconjugados | |
| MA27729A1 (fr) | Compositions pharmaceutiques solides contenant un agoniste des recepteurs de la s1p et un alcool de sucre | |
| GEAP202415955A (en) | Pharmaceutical combination of prmt5 inhibitors | |
| EE05103B1 (et) | Famatseutilised kompositsioonid, mis sisaldavad asetidiini derivaate, asetidiini derivaadid ja nende valmistamise meetodid | |
| MA52424B1 (fr) | Compositions pharmaceutiques comprenant du (2s)--((1s)-1-cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl)-1,4-oxazepane-2-carboxamide | |
| UA93496C2 (uk) | Стерильний склад модифікатора імунної відповіді та способи одержання зазначеного складу | |
| ECSP024352A (es) | Nueva composicion farmaceutica | |
| BE1005808A5 (fr) | Medicaments pour traiter les troubles gastro-intestinaux. | |
| US20100298317A1 (en) | Method of treating polycystic kidney diseases with ceramide derivatives | |
| WO2009055721A3 (en) | 5-lipoxygenase activating protein (flap) inhibitor | |
| MA42946B1 (fr) | Sels et formes solides d'un antibiotique de type monobactame | |
| MA53927B1 (fr) | Composition pharmaceutique pour une administration par voie orale comprenant un dérivé d'aminopyrimidine ou son sel | |
| NZ776354A (en) | Pharmaceutical formulations containing relacorilant, a heteroaryl-ketone fused azadecalin compound | |
| SG162616A1 (en) | Combinations comprising epothilones and pharmaceutical uses thereof | |
| ATE489096T1 (de) | Pharmazeutische magensaftresistent überzogene zusammensetzung enthaltend prostaglandin-analoga als chloridkanalöffner | |
| JP2015536949A (ja) | 細菌感染症のための抗生物質を用いる方法および組成物 | |
| MX2021014944A (es) | Metodos para tratar cancer usando inhibidores de prmt5. | |
| MA30691B1 (fr) | Compositions pharmaceutiques contenant un anticorps monoclonal anti-idiotypique anti-ca-125 et de l'aluminium. | |
| MA62176A1 (fr) | Composition pharmaceutique contenant de l'acétominophène et de l'ibuprofène | |
| US20190133995A1 (en) | Methods for the treatment of infection | |
| MA29567B1 (fr) | (5z)-5-(6-quinoxalinylmethylidene)-2-[(2,6-dichlorophenyl) amino]-1,3-thiazol-4(5h)-one | |
| WO2022115681A3 (en) | Methods and compositions for oral pilocarpine liquid |